Article

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer Patients

2024-12-11

Abstract excerpt

<title>Abstract</title> <p>HER2 status is an important therapeutic and prognostic biomarker in the molecularly heterogeneous disease of breast cancer. HER2-targeted therapies such as trastuzumab, pertuzumab and trastuzumab deruxtecan have transformed survival outcomes for HER2-positive breast cancers, which account for 15–20% of cases. Similarly, HER2-negative breast cancers do not have HER2 as a potential therap...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c24688c8-eb19-5f63-8648-5f3f5c980a9f
DOI: 10.21203/rs.3.rs-5573127/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsDOI 10.21203/rs.3.rs-5573127/v1Read

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.Semantic proximity Read

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read

Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional AnalysisSemantic proximity Read

Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysisSemantic proximity Read

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read

Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity Read